Cytoreductive Surgery

A Comprehensive Overview for Modern Oncologic Care

Cytoreductive surgery (CRS) has emerged as a pivotal procedure in the management of advanced cancers, particularly those involving the peritoneal cavity. It is designed to remove visible tumor deposits, thereby reducing the overall disease burden and enhancing the effectiveness of adjunct therapies such as hyperthermic intraperitoneal chemotherapy (HIPEC).

What is Cytoreductive Surgery?

Cytoreductive surgery is a specialised surgical technique aimed at excising macroscopic tumor deposits within the abdomen and pelvis. Unlike conventional surgeries that focus on resection of a single organ or localized tumor, CRS addresses disseminated disease across multiple peritoneal surfaces. The primary goal is to achieve complete or near-complete cytoreduction, which significantly improves survival outcomes in selected patients.

Cytoreductive Surgery (CRS) –Schematic view 

1️⃣ Definition and Core Concept

  • Cytoreductive Surgery (CRS) is an advanced surgical procedure designed to remove all visible tumor deposits from the peritoneal cavity.

  • Purpose: To decrease tumor load, improve response to chemotherapy, and enhance long-term survival.

  • Philosophy: “Maximum tumor reduction for maximum therapeutic gain.”

Core Value: Precision, completeness, and patient-centered care.

2️⃣ Indications and Disease Spectrum

  • Primary Indications:

    • Pseudomyxoma Peritonei (PMP)

    • Peritoneal Mesothelioma

    • Colorectal Peritoneal Carcinomatosis

    • Ovarian Cancer with Peritoneal Spread

    • Gastric or Appendiceal Peritoneal Tumors

  • Eligibility Criteria:

    • Limited, resectable peritoneal disease

    • Absence of extra-abdominal metastasis

    • Good performance status (ECOG 0–1)

Core Value: Evidence-based patient selection improves outcomes.

3️⃣ Preoperative Assessment and Optimization

  • Diagnostic Workup:

    • Imaging: CT, MRI, or PET for disease mapping.

    • Lab Tests: CBC, renal and hepatic profile, tumor markers (CEA, CA-125).

    • PCI (Peritoneal Cancer Index) scoring — quantifies disease extent (0–39).

  • Optimization Measures:

    • Nutritional support and infection control

    • Cardio-pulmonary fitness evaluation

    • Multidisciplinary team consultation (Surgeon, Oncologist, Radiologist, Anesthesiologist)

Core Value: Preparation and teamwork ensure safety and precision.

4️⃣ Surgical Procedure Overview

  • Step 1: Midline laparotomy and exploration of abdominal cavity.

  • Step 2: Peritonectomy procedures — removal of affected peritoneal surfaces.

  • Step 3: Organ resections as necessary (omentum, spleen, small bowel, uterus, ovaries).

  • Step 4: Aim for CC-0 (no residual disease) or CC-1 (<2.5 mm nodules) cytoreduction.

  • Step 5: Combine with HIPEC (Hyperthermic Intraperitoneal Chemotherapy) — 41–43°C heated chemotherapy circulated for 60–90 minutes to kill microscopic residual cells.

Core Value: Oncologic completeness guided by surgical discipline.

5️⃣ Postoperative Management and Recovery

  • Immediate Care:

    • ICU monitoring for fluid balance, renal output, and hemodynamic stability.

    • Pain control and respiratory support as needed.

  • Intermediate Recovery:

    • Gradual reintroduction of oral intake.

    • Early ambulation and physiotherapy to prevent complications.

    • Antibiotic prophylaxis and DVT prevention.

  • Long-Term Follow-Up:

    • Regular imaging and tumor marker evaluation every 3–6 months.

    • Nutritional and psychological rehabilitation.

Core Value: Holistic recovery—physical, nutritional, and emotional.

6️⃣ Complications and Risk Reduction

  • Possible Complications:

    • Bleeding, anastomotic leak, infection, renal dysfunction, or sepsis.

  • Prevention Strategies:

    • Strict aseptic technique, intraoperative temperature control, vigilant fluid management, and experienced surgical team involvement.

  • Mortality Rate: <5% in expert centers; Morbidity: 20–40% depending on disease extent.

Core Value: Safety through skill and structured perioperative care.

7️⃣ Outcomes and Prognostic Indicators

  • Success Determinants:

    • Completeness of cytoreduction (CC-0/CC-1)

    • Tumor biology and response to HIPEC

    • Institutional experience and multidisciplinary care

  • Survival Rates:

    • 5-year survival: 40–60% for pseudomyxoma peritonei and mesothelioma.

    • Median survival: 30–45 months for colorectal and ovarian peritoneal metastasis.

  • Quality of Life: Marked improvement with reduction in ascites, pain, and tumor-related symptoms.

Core Value: Survival with dignity, comfort, and hope.

8️⃣ Conclusion and Ethical Perspective

  • Cytoreductive Surgery represents a major advancement in oncologic surgery, offering curative potential in diseases once deemed terminal.

  • Success relies on precise selection, expert technique, and compassionate postoperative care.

Core Value: Innovation, integrity, and individualized care form the foundation of CRS practice.